180 related articles for article (PubMed ID: 26334294)
21. Survival analysis of contralateral prophylactic mastectomy: a question of selection bias.
Kruper L; Kauffmann RM; Smith DD; Nelson RA
Ann Surg Oncol; 2014 Oct; 21(11):3448-56. PubMed ID: 25047478
[TBL] [Abstract][Full Text] [Related]
22. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period.
Fortunato L; Mascaro A; Poccia I; Andrich R; Amini M; Costarelli L; Cortese G; Farina M; Vitelli C
Ann Surg Oncol; 2012 Apr; 19(4):1107-14. PubMed ID: 21913022
[TBL] [Abstract][Full Text] [Related]
23. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival.
García-Fernández A; Lain JM; Chabrera C; García Font M; Fraile M; Barco I; Torras M; Reñe A; González S; González C; Piqueras M; Veloso E; Cirera L; Pessarrodona A; Giménez N
Breast J; 2015; 21(5):533-7. PubMed ID: 26190560
[TBL] [Abstract][Full Text] [Related]
24. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
[TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
26. Contralateral breast cancer: factors associated with stage and size at presentation.
Mertens WC; Hilbert V; Makari-Judson G
Breast J; 2004; 10(4):304-12. PubMed ID: 15239788
[TBL] [Abstract][Full Text] [Related]
27. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.
Gao X; Fisher SG; Emami B
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1038-45. PubMed ID: 12829139
[TBL] [Abstract][Full Text] [Related]
28. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
29. Metachronous contralateral breast cancer as first event of relapse.
de la Rochefordière A; Mouret-Fourme E; Asselain B; Scholl SM; Campana F; Broët P; Fourquet A
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):615-21. PubMed ID: 8948346
[TBL] [Abstract][Full Text] [Related]
30. [Bilateral carcinoma of the breast].
Cucinotta E; Calbo L; Palmeri R; Pergolizzi FP; Melita G
Chir Ital; 1997; 49(1-2):9-14. PubMed ID: 12743870
[TBL] [Abstract][Full Text] [Related]
31. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
[TBL] [Abstract][Full Text] [Related]
32. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands.
Schaapveld M; Visser O; Louwman WJ; Willemse PH; de Vries EG; van der Graaf WT; Otter R; Coebergh JW; van Leeuwen FE
Breast Cancer Res Treat; 2008 Jul; 110(1):189-97. PubMed ID: 17687645
[TBL] [Abstract][Full Text] [Related]
33. Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.
Skowronek J; Piotrowski T
Neoplasma; 2002; 49(6):426-31. PubMed ID: 12584593
[TBL] [Abstract][Full Text] [Related]
34. A case-control study of unilateral and bilateral breast carcinoma patients.
Newman LA; Sahin AA; Cunningham JE; Bondy ML; Mirza NQ; Vlastos GS; Whitman GJ; Brown H; Buchholz TA; Lee MH; Singletary SE
Cancer; 2001 May; 91(10):1845-53. PubMed ID: 11346865
[TBL] [Abstract][Full Text] [Related]
35. Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry.
Prater J; Valeri F; Korol D; Rohrmann S; Dehler S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):365-71. PubMed ID: 26298838
[TBL] [Abstract][Full Text] [Related]
36. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
37. Survival from contralateral breast cancer.
Gajalakshmi CK; Shanta V; Hakama M
Breast Cancer Res Treat; 1999 Nov; 58(2):115-22. PubMed ID: 10674875
[TBL] [Abstract][Full Text] [Related]
38. Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era.
Beal SH; Martinez SR; Canter RJ; Chen SL; Khatri VP; Bold RJ
Med Oncol; 2010 Dec; 27(4):1420-4. PubMed ID: 20049562
[TBL] [Abstract][Full Text] [Related]
39. Outcomes for patients who develop both breast and colorectal cancer.
Fisher CS; Wachtel MS; Margenthaler JA
Ann Surg Oncol; 2012 Jan; 19(1):242-8. PubMed ID: 21701928
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
